Sixteen cases of hepatoma presenting as craniospinal metastasis without obvious hepatic involvement were reviewed. Metastatic spread ofhepatoma to the cerebrum was found in one case, to the cranium in six cases, and to the vertebrae in nine cases. All of these cases had mildly abnormal liver function when first evaluated. Of those patients with hepatoma, 56% had evidence of hepatomegaly. Alpha fetoprotein was present, at levels greater than 320 ng/ml, in 69%. cerebral, cranial, and vertebral, including one, six, and nine cases respectively. Routine liver function tests and a serological test for hepatitis B surface antigen were done on the first day of admission. Additional liver investigations, including serum alpha fetoprotein (AFP) measurements, liver-spleen CT, abdominal sonography, or coeliac angiogram, were performed after the tissue diagnosis had been made. AFP was classified as "positive" if the level was above 320 ng/ml.
six cases, and to the vertebrae in nine cases. All of these cases had mildly abnormal liver function when first evaluated. Of those patients with hepatoma, 56% had evidence of hepatomegaly. Alpha fetoprotein was present, at levels greater than 320 ng/ml, in 69%. Ninety four per cent died of the primary liver disease within one year. For any patient who develops craniospinal metastasis ofunknown origin in a geographical area where hepatoma is a common disease, hepatoma should be considered in the differential diagnosis. 
Results

Clinical features
The clinical manifestations and the site of metastasis in each patient are listed in the table.
In the cerebral group, the patient presented with progressive weakness and numbness in the left arm, followed by intracranial haemorrhage and disturbed consciousness. Tumour bleeding was confirmed by histological study.
In the cranial group, two different sites of metastasis were found, the calvarium and the base of the skull; there were three instances of each. Two of the three patients with metastasis to the calvarium had a progressively enlarging mass in the vertex. During the operation, no intradural invasion was found. The third patient had symptoms and signs suggestive of intracranial tumour, and intradural extension and parenchymal involvement of the brain were demonstrated. All three patients with metastasis to the base of the skull presented with symptoms of cranial nerve involvement.
Those with retrobulbar or parasellar involvement developed diplopia, ptosis and limitation of eye movements. The patient with metastasis to the jugular fossa and hypoglossal canal manifestated dysarthria and tongue atrophy.
In the vertebral group, one metastasis was in the cervical spine, two in the thoracic region, four in the lumbar vertebrae, and two in the sacrum. All of these patients experienced back pain or neck pain as the first symptom, followed by symptoms of spinal cord involvement. The patient with cervical involvement presented with arm weakness. The patients with lesions in the thoracic region had progressive paraparesis as the predominant symptom. With metastasis of the lumbar vertebrae, all except one patient presented with paraparesis or sphincter problems, or both. This patient's symptoms mimicked a herniated intervertebral disc. With lesions in the sacral region, sphincter problems were the main complaint.
Hepatomegaly is an important symptom 13 patients had metastasis to the vertebrae and epidural space, one to the cranium, and five to the cerebrum.
In Chang and Chen's series,' vertebrae and the epidural space were involved in four cases, the cranium in two, and the cerebrum in one. A similar distribution was noted in our series.
The metastatic spread of primary hepatoma might initially result from invasion of the hepatic and portal veins. The regional lymph nodes, including periportal and peripancreatic nodes, were extensively involved. Pulmonary vascular metastasis then develops after the venous structures have been invaded and may be followed by widespread hematogenous spread with metastasis to the bone and brain.8
Some explanations offered for the rarity of brain metastasis in patients with hepatoma include a rapidly fatal course, most patients having died within six months of the onset of symptoms.4 It is also possible that there have been more cases of metastasis to the nervous Lee system, which perhaps have been overlooked or obscured by the symptoms of hepatic or other metabolic encephalopathy.9 1O When there is an absence of clinical manifestations, brain metastasis from primary hepatoma may be of little clinical significance. Most cases were found at necropsy, " so there is a discrepancy between the incidence of clinical neurological complications and incidence at necropsy.6
In rare instances, an apoplectic onset of symptoms from a cerebral metastasis has been reported. 6 The first patient in our series presented this way, with a history of progressive left arm weakness and numbness followed by sudden onset of left hemiplegia and disturbed consciousness.
Metastasis to the skull may be found either in the calvarium or in the base. When in the calvarium, it may be either extradural only,6 12 as in cases 3 and 4, or may exhibit intracerebral extension6 with raised intracranial pressure or focal symptoms, as in case 2 of our series. When metastasis to the base of the skull occurs, the cranial nerves may be involved, without associated increase of intracranial pressure, as in cases 5, 6 and 7 of this series.
Hepatoma is believed to be an unusual primary among cases of spinal cord compression by metastatic tumours. In different series among white groups, 1 2-3-0% were reported. ' 6 This is in contrast to the much higher incidence of 17-1% among African cases."3
The nine cases reported here represent 15% of 59 cases of metastatic cancer to the spinal column (unpublished data) in our hospital series between 1981 and 1988, which is close to that described in the African cases.'3 The vertebrae have been reported by Carnahan"
and Green'7 as the most common site of bone metastasis of hepatoma cells through the vertebral vein. From the overview of this series, the lumbar spine seems to be the most frequent site of vertebral metastasis, representing 44% (4/9) of cases. Clinically, all the patients with vertebral metastasis had a history of back pain or neck pain as the first symptom followed by symptoms of spinal cord compression. When the cervicothoracic spine was involved, myelopathy was the predominant symptom. When metastasis to the lumbar spine occurred, cauda equina syndrome was the main presentation. When sacrum metastasis developed, sphincter problems were the chief complaint.
Routine laboratory studies may provide little diagnostic help before biopsy. Although abnormal liver function may be detectable in the early stage, these findings do not differ from chronic liver disease. The most distinctive diagnostic laboratory test presently available for hepatoma is the immunoserological assay for AFP. The serologically positive percentage varied from 50% to 79-6% in different series.'
In our series, 69% of patients with hepatoma were found to be positive. Serum AFP levels have been shown to be correlated with liver weight in AFP-producing hepatoma. Sometimes it is negative or low in patients with early hepatoma. However, the measurement of serum AFP is useful in screening for early hepatoma. Even small hepatomas sometimes may present with elevated serum AFP level, which can be determined easily.
Liver ultrasound is a sensitive and easy method for the detection of hepatic tumours. Shen et al'8 reported a 93-9% (31/33) detection rate even with small hepatomas. Only a 54% detection rate was described by Kobayashi et al. '9 In this series, 87-5% (14/16) of patients had a positive finding. Coeliac angiography is an established method for the diagnosis of hepatoma. A 77% detection rate was reported by Kobayashi et al"9 and the second case in our series was detected only by this method. Although it is sensitive and specific in detection of hepatoma, it is invasive and impractical for the follow up of high risk populations of patients.
It is well known that hepatoma runs a rapidly fatal course. In 83-5% of patients, death occurred within 6 months of the onset of symptoms.5 In our series, 93-8% of patients died within one year. The average survival is 6-3 months after the onset of symptoms. The ultimate prognosis of patients with metastasis to the central nervous system is dependent on the natural history of the primary lesion.
